Scientific topics
Keywords
ITMO
Jessica zucman-rossi Professor in Oncology, MD, PhD
Course and current status
Family name, First name: ZUCMAN-ROSSI, Jessica
Researcher unique identifier(s): https://orcid.org/0000-0002-5687-0334
URL for web site: https://zucmanlab.com/
Education and key qualifications
2009 Professor of Medicine in Oncology
2018 Accreditation to direct research (HDR), Population Genetics
1994 PhD in fundamental bases of oncogenesis
1994 Medical specialty: Internal Medicine
1987-1994 Residency in Internal Medicine and Oncology, Paris
- Current position(s)
Since 2019 Director, Centre de recherche des Cordeliers, Paris
Since 2009 Professor, Université Paris Cité, Oncology, Paris
Since 2009 Praticienne Hospitalière, APHP, HEGP Hospital, Paris
Since 2007 Team leader, Functional genomics of solid tumors, Paris
Since 2022 Member of the National deontology college at the French Ministry of Research
Since 2025 Member of the HCERES college
Since 2025 President of the Ligue Contre le Cancer scientific Committee Ile de France
- Previous position(s)
2022-2023 President of the International Liver Cancer Association (ILCA)
2019-2024 Member of the FNRS committee for physiology and Cancer
2012-2016 Chair of the national Inserm scientific committee for Cancer, Genetics and Bioinformatics
2020-2022 Chair of the Foundation ARC Committee for Research Orientation
2004-2009 Inserm Director of Research (DR2->DR1), Paris
1998-2004 Inserm Research Scientist (CR1), Paris
Peer recognition
Prizes and Awards
1993 French academy of science, Award Eugène et Amélie Dupuis
1998 Award young researcher Ligue Nationale Contre le Cancer
2004 French Academy of Science, Award René Turpin for cancer research
2012 Award Inserm Research
2014 Elected fellow of the European Academy of Cancer Sciences
2015 Award Charles Oberling
2016 « Coups d’élan » Fondation Schueller-Bettencourt
2018 René et André Duquesne, Comité de Paris Ligue Contre le Cancer
2018 Chevalier de la Légion d’honneur
2019 Ismar Boas Medal, Germany
2019 Docteur Honoris Causa Université Catholique de Louvain
2021-2025 Awarded by Clarivate “most highly cited researcher”
2021 French Academy of Medicine, Albert 1er de Monaco Award
2024 Lucie Bolte Prize, Hannover, Germany
2025 EASL European Assciation for study of the Liver: Recognition award, Amsterdam
Major recent fundings
- EU-GENIAL: Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinoma. Horizon-Miss-2021-Cancer-02. WP1: Zucman-Rossi coordinator with Luca Valenti
- EU-THRIVE: Tumour-host interactions in liver cancer of childhood and adults. Ref. 101136622. Horizon-Miss-2023-Cancer-01. Llovet JM (Coordinator), WP3: Zucman-Rossi coordinator with Manel Esteller
- FR-cisMUTEC, Deciphering cisplatin mutational signature in hepatoblastoma for early diagnosis of chemoresistance and new treatment. Pediatric High Risk/High Gain INCA 2022. Zucman-Rossi (Coordinator) with Hirsch T (co-PI). 2023-2025
Presentations as invited speaker
More than 260 invited lectures at international meetings (EACR keynote speaker 2024, AACR, ASCO GI, EASL, AASLD, EMBO, FASEB, Keystone, Falk symposium, Leopoldina symposium, CRCL, APASL, Forbeck Forum,... ) or international institutes and universities (Mayo Clinic, Mount Sinai NY, Yale, Rockefeller NY Univ, NIH-NCI, NCC Singapore, UCLondon, Frukfurt univ, Newcastle Univ, CNIO, Asan Hospital, Taiwan Univ, Tel Aviv Univ, Scripps…)
Editorial activities
JHEP Reports new OA journal EASL, Geneva 2018 2023 Editor-in-Chief (IF 2022=9.9)
Journal of Hepatology, EASL, Geneva 2014 2019 Senior Editor JHEP (IF 2022=30)
Journal of Hepatology, EASL, Geneva 2010 2014 Associate Editor JHEP (IF 2014=10)
Reviewer for >50 journals including Nature, Nature Medicine, Nature Genetics, Nature Review Cancer, Nature Communications, Cell, Cancer Cell, Cancer Discovery, Lancet, Lancet Oncology, Clinical Cancer Research, Gastroenterology, Gut, Hepatology, JAMA, Journal of Clinical Investigation, Journal of Clinical Oncology, Journal of Experimental Medicine, Journal of Hepatology, PNAS, Science Translational Medicine.
Teaching activities and mentoring
Member or chair of jury for ~60 PhD or HDR jury committees between 2002 and 2024
Between 1997 and 2024, supervision of 18 post-doctorates, 26 PhD students, and 21 master Students. Among them, ~30 are researchers in university laboratories and/or hospitals, ~8 are researchers in private companies.
Co-organizer of international scientific conferences including
ILCA annual meetings 2015-2023 (400 to 900 participants each year); French-NTU symposium, Taiwan 2024; Holistic integrative Oncology, China 2024; EASL symposium 2024; AACR symposium 2022; EASL Basic Science Course 2020; Vice-Chair and chair of the Steering committee of the SIG neoplasm at AASLD 2019-2021 organization of several symposia (American Association for Study of liver disease); 5th International Conference on Liver and Cardiovascular Science, Wuhan, China, April 2019; HCC Summit EASL 2019; Cold Spring Harbor Asia liver metabolism and cancer, April 2016, Suzhou, China; Gilles Thomas’ symposium 2015 et 2017; FASEB Liver Summer Conference 2012
Career production (2025): 511 published articles, >47,000 citations in the literature, h-index 93 (Web of Science), 109 (Google Scholar), 7 patents with international extension, two licensed
Scientific summary
Jessica Zucman-Rossi, MD, PhD was trained in internal medicine and oncology. Her research area mainly investigates the genetics and biology of liver cancers and benign tumors, in adults and children. Her team has a major interest in understanding the relations between exposure to toxic agents, diet habits, genetic predisposition, chronic diseases, including viral infections, and their cooperation in the mechanisms of carcinogenesis. Recently, they identified genetic predisposition to benign and malignant liver tumor, including HNF1A in adenoma, and WNT3A/WNT9A in hepatocellular carcinoma. They also performed seminal discoveries in the identification of tumor molecular classifications and their translation into the clinical care of patients. Her team also has a strong interest in deciphering the cell plasticity and heterogeneity of pediatric liver cancers and in finding new therapeutic targets in these diseases. She coordinates several National (PELICAN in children liver cancer) and European scientific projects (EU GENIAL).
The development of approaches based on the functional genomics of human tumors has enabled them to identify new mechanisms involved in carcinogenesis and then to translate these results into the clinics to improve patient management, prevention, diagnosis, prognostic prediction and treatment of these tumors.
